121697-55-0

Basic information

• Product Name: 2-[(3-chlorobenzyl)oxy]benzoic acid
• Synonyms: 2-[(3-chlorobenzyl)oxy]benzoic acid
• CAS NO: 121697-55-0
• Molecular Formula: C₁₄H₁₁ClO₃
• Molecular Weight: 262.68834
• Mol File: 121697-55-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[(3-chlorobenzyl)oxy]benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(3-chlorobenzyl)oxy]benzoic acid(121697-55-0)
• EPA Substance Registry System: 2-[(3-chlorobenzyl)oxy]benzoic acid(121697-55-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 121697-55-0(Hazardous Substances Data)

Usage

Physical appearance

white to off-white crystalline powder

Classification

benzene derivative, belongs to the class of organic compounds known as benzoic acids

Uses

intermediate in the synthesis of pharmaceuticals and other organic compounds, production of medicines, preparation of other chemicals (fragrances, dyes, plastics), potential applications in medicine and agriculture due to pharmacological and pesticidal properties.

Upstream product

• 952720-43-3 methyl 2-{[(3-chlorophenyl)methyl]oxy}benzoate 
• 119-36-8 methyl salicylate 
• 766-80-3 1-bromomethyl-3-chlorobenzene 

Downstream Products

• 1198420-19-7 ethyl (3-chloro-4-{[(2-{[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetate 
• 1198420-20-0 (3-chloro-4-{[(2-{[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid 

Relevant articles and documents

Design, synthesis and molecular docking of salicylic acid derivatives containing metronidazole as a new class of antimicrobial agents

A series of novel salicylic acid derivatives containing metronidazole as Staphylococcus aureus Tyrosyl-tRNA synthetase (TyrRS) inhibitors have been synthesized and evaluated their biology activities as potential antibacterial agents. Among these compounds

NOVEL EP4 RECEPTOR AGONIST COMPOUNDS

A compound selected from the group consisting of: (3-chloro-4-{[(5-chloro-2-{[(2- chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid; {4-[({5-chloro-2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; {3-chloro-4-[({5-chloro-2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; (3-chloro-4-{[(5-chloro-2-{[(3- chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid; {4-[({2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; (4-{[(5-chloro-2-{[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}-2- fluorophenyl)acetic acid; {3-chloro-4-[({2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; (3-chloro-4-{[(2-{[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid; {4-[({2-chloro-6-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; (4-{[(2-chloro-6-{[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid; {4-[({5-chloro-2-[(phenylmethyl)amino]phenyl}carbonyl)amino]phenyl}acetic acid; (4-{[(5-chloro-2-{[(3-chlorophenyl)methyl]amino}phenyl)carbonyl]amino}phenyl)acetic acid; and (4-{[(5-chloro-2-{[(2-chlorophenyl)methyl]amino}phenyl)carbonyl]amino}phenyl)acetic acid, or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.